3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
298
Carcinoma, Non-Small-Cell Lung
224
Prostatic Neoplasms
154
Neoplasms
154
Multiple Myeloma
116
Neoplasm Metastasis
83
Colorectal Neoplasms
80
Leukemia, Myeloid, Acute
73
Lung Neoplasms
71
Parkinson Disease 4, Autosomal Dominant Lewy Body
68
Melanoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Follicular
62
Lymphoma, Non-Hodgkin
61
Papillomavirus Infections
59
Leukemia
59
Pain
52
Lymphoma
52
Uterine Cervical Neoplasms
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
49
Ovarian Neoplasms
46
Carcinoma, Hepatocellular
46
Keratosis, Actinic
44
Carcinoma, Renal Cell
44
Recurrence
43
Head and Neck Neoplasms
43
Stomach Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
34
Urinary Bladder Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
32
Interventions
Temozolomide
1
Irinotecan
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
Rare Diseases
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts